Clinical trial · Interventional
Geldanamycin Analogue in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma
A Phase I and Pharmacologic Study of 17-(Allylamino)-17-Demethoxygeldanamycin (AAG, NSC 330507) in Adult Patients With Solid Tumors
NCT00019708CI-TRIAL-00012987terminatedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Phase I trial to study the effectiveness of geldanamycin analogue in treating patients who have advanced solid tumors or non-Hodgkin's lymphoma. Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die.
Conditions
Conditions (28)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | ALIAS | 0.90 |
| Nodal Marginal Zone B-cell Lymphoma | Nodal Marginal Zone Lymphoma | ALIAS | 0.90 |
| Non-Hodgkin Lymphoma | Non-Hodgkin Lymphoma | ONTOLOGY_EXACT | 0.90 |
| Recurrent Adult Burkitt Lymphoma | Adult Burkitt Lymphoma | CURATED_BROADER | 0.78 |
| Recurrent Adult Diffuse Large Cell Lymphoma | — | UNRESOLVED | — |
| Recurrent Adult Diffuse Mixed Cell Lymphoma | — | UNRESOLVED | — |
| Recurrent Adult Diffuse Small Cleaved Cell Lymphoma | Non-Hodgkin Lymphoma | CURATED_BROADER | 0.78 |
| Recurrent Adult Immunoblastic Large Cell Lymphoma | Adult Immunoblastic Lymphoma | CURATED_BROADER |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| tanespimycin | Drug | Tanespimycin | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Treatment (tanespimycin)
- description
- Patients will receive infusions of tanespimycin analogue twice a week in weeks 1 and 3.
- interventionNames
- Drug: tanespimycin
Primary outcomes (1)
- measure
- Maximum tolerated dose of tanespimycin
- timeFrame
- 28 days
- description
- DLT are defined as any greater than or equal to grade 3 non-hematologic toxicity (except for alopecia of any grade, grade 3 nausea or vomiting during less than maximal antiemetic therapy, and grade 3 fever in the absence of neutropenia and infection), any grade 4 hematologic toxicity (except for anemia of any grade), or the inability to resume treatment by day 42 (longer than two week delay) because of drug related toxicity.
Secondary outcomes (2)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 19 Years
Show eligibility criteria text
Criteria: * Platelet count at least 100,000/mm\^3 * No leukemia * No active CNS involvement with tumor * ECOG 0-2 * Life expectancy: at least 3 months * Absolute neutrophil count at least 2,000/mm\^3 * No New York Heart Association class III or IV heart failure * No history of myocardial infarction within the past year * Bilirubin =\< upper limit of normal (ULN) * AST no greater than 2 times ULN (no greater than 98 U/L) * No uncontrolled dysrhythmias * No poorly controlled angina * No serious ventricular arrhythmia (i.e., ventricular tachycardia (VT) or ventricular fibrillation (VF) \>= 3 beats in a row) * QTc interval =\< 450 msec for men or =\< 470 msec for women * LVEF \>= 40% by MUGA * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * HIV negative * No other serious medical condition that would preclude study participation * No serious hypersensitivity to egg products * No concurrent anticancer immunotherapy * At least 4 weeks since prior chemotherapy and recovered * No other concurrent anticancer chemotherapy (e.g., cyclophosphamide, doxorubicin, vincristine, and prednisone \[CHOP\] or mechlorethamine, vincristine, procarbazine, and prednisone \[MOPP\]) * No concurrent anticancer hormonal therapy * Concurrent glucocorticoids as antiemetics for nonmalignant disease allowed * At least 4 weeks since prior radiotherapy and recovered * No concurrent radiotherapy * No concurrent major surgery * No concurrent anticancer glucocorticoids * Creatinine =\< ULN or Creatinine clearance at least 60 mL/min * No concurrent medications that cause QTc prolongation * Histologically confirmed advanced solid tumor for which no curative therapy exists * Non-Hodgkin's lymphoma allowed * No concurrent drugs that interfere with hepatic CYP3A4 metabolism (e.g., grapefruit juice, ketoconazole, fluconazole, itraconazole, cyclosporine, erythromycin, clarithromycin, cimetidine, terfenadine, astemizole, indinavir, or nelfinavir mesylate)
References
Publications (0)
Data not yet available
No reference posted for this study.